XERS · Xeris Biopharma Holdings, Inc.
$7.45
-2.87% last session
End-of-day data · close of 2026-09-11
Market cap
$1B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
19.7
Dividend yield
—
Beta
0.85
Avg volume
2M
Employees
0K
Daily Change %
-2.87%
5 Days Change
-9.61%
10 Days Change
-8.65%
30 Days Change
-8.10%
60 Days Change
-7.55%
Month to Day Change
-8.54%
Year to Day Change
-1.78%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — XERS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-10
Latest call per bank · past 12 months
Barclays
Overweight$12.00
+56.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-10 | Leerink Partners | Maintains | Outperform | $12.00 → $16.00 |
| 2026-08-20 | Barclays | Maintains | Overweight | $9.00 → $12.00 |
| 2026-03-02 | HC Wainwright & Co. | Reiterates | Buy | $10.00 |
| 2026-01-09 | HC Wainwright & Co. | Reiterates | Buy | $10.00 |
| 2025-12-09 | Barclays | Initiates | Overweight | $0.00 → $9.00 |
| 2025-11-07 | Oppenheimer | Maintains | Outperform | $18.00 |
| 2025-11-07 | HC Wainwright & Co. | Maintains | Buy | $10.00 |
| 2025-11-07 | Piper Sandler | Maintains | Neutral | $6.00 → $8.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 30 — oversold territory; selling pressure looks stretched.
- Price vs 50-day MA: Trading 11.3% below the 50-day MA ($8.40).
- Price vs 200-day MA: Trading 5.5% above the 200-day MA ($7.06).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.14) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($5.29) and high ($9.90).
XERS Price Chart
Loading chart for XERS…
Fundamentals
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$58B 16.8% YTD
TEVA
Teva Pharmaceutical Industries
$42B 18.1% YTD
HLN
Haleon plc
$41B -6.9% YTD
ZTS
Zoetis Inc.
$30B -40.8% YTD
UTHR
United Therapeutics Corporation
$22B 4.0% YTD
VTRS
Viatris Inc.
$19B 35.6% YTD
NBIX
Neurocrine Biosciences, Inc.
$16B 9.4% YTD
ELAN
Elanco Animal Health Incorporat
$11B 4.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.